Pulmonary arterial hypertension: Changing approaches to management

Kardiologiya

Volumn 51, Issue 1, 2011, Pages 100-108

  Sidorenko, B A ^a,b   Preobrazhensky, D V ^a,b   Batyraliev, T A ^a,b   Belenkov, Yu N ^a,b  

^a Presidential Medical Center of Russia   (Russian Federation)

^b I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Arterial hypertension; Bosentan; Epoprostenol; Sildenafil

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN; VASODILATOR AGENT;

CLASSIFICATION; DRUG ANTAGONISM; DRUG COMBINATION; HEART; HEART CATHETERIZATION; HEART DISEASE; HUMAN; LUNG; MASS COMMUNICATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PULMONARY ARTERY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOSIS; VASCULARIZATION;

ANTICOAGULANTS; CALCIUM CHANNEL BLOCKERS; DIFFUSION OF INNOVATION; DRUG THERAPY, COMBINATION; HEART; HEART CATHETERIZATION; HEART DISEASES; HUMANS; HYPERTENSION, PULMONARY; LUNG; PHOSPHODIESTERASE 5 INHIBITORS; PROSTAGLANDINS; PULMONARY ARTERY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ENDOTHELIN; THROMBOSIS; VASODILATOR AGENTS;

EID: 79960961614     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Rich S. (ed.). Primary pulmonary hypertension. Executive summary from World symposium - Primary pulmonary hypertension 1998. France, WHO: Evian 1998.
2. The Task Force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004;25:2243-2278.
3. Simonneau G., Gatè N., Rubin L. J. et al. Clinical classification of pulmonary hypertension. JACC 2004;52:5-12.
4. McLaughlin V. V., Archer S. L., Badesch D. B. et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Assoiation. Circulation 2009;109:192-230.
5. Simonneau G., Robbins I. M., Beghetti M. et al. Updated clinical classification of pulmonary hypertension. JACC 2009;54;suppl. 1:S43-S54.
6. Burst R. J., McGoon M., Torbicki A. et al. Diagnosis and differential assessment of pulmonary arterial hypertension. JACC 2004;12:40S-47S.
7. Stewart S. Pulmonary arterial hypertension. London and New York 2005.
8. Gate N., Hoeper M. M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493-2537.
9. Mayer E. Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2010;19:64-67.
10. Fuster V., Steele P. M., Edwards W. D. et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-587.
11. Rich S., Kaufinann E., Levy P. S. The effect of high dosed of calciumchannel blockers on survival in primary pulmonary hypertension. New Engl J Med 1992;327:76-81.
12. Frank H, Mlczpch J., Huber K. et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997;112:714-721.
13. Jonhson S. R., Mehta S., Granton J. T. Anticoagulantion in pulmonary arterial hypertension: a qualitative systemic review. Eur Resp J 2009;38:999-1004.
14. Jones M., McEwan P., Morgan C. L. et al. Evaluation of the pattern of treatnment, level of anticoagulation control, and outcomes of treatment with warfarin in patients with non-valvular atrial fibrillation: a record linkage study in a large British population. Heart 2005;91:472-477.
15. Rich S., Seiditz M., Dodin E. et al. The short-term effects of digoxin in right ventricular dysfunction from pulmonary hypertension. Chest 1998;114:787-792.
16. Badesch D. B., Ahman S. H., Ahearn G. S. et al. Medical therapy for pulmonary artery hypertension. ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S-62S.
17. Fortin T. A., Tapson V. F. Intravenous prostacyclin for pulmonary arterial hypertension. In: Pulmonary circulation. Diseases and their treatment. Peacock A. J., Rubin L. J. (eds). Second edition. London: Arnold 2004:255-267.
18. Rubin L. J., Mendoza J., Hood M. et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial therapy. Ann Intern Med 1990;112:485-491.
19. Barst R. J., Rubin L. J., Long WA. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. New Engl J Med 1996;334:296-301.
20. Badesch D., Tapson V. F., McGoon M. D. et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial therapy. Ann Intern Med 2000;132:425-434.
21. McLaughlin V. V., Genther D. E., Panella M. M., Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. New Engl J Med 1998;338:273-277.
22. Shapiro S. M., Oudiz R. J., Cao T. et al. Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion. JACC 1997;30:343-349.
23. McLaughlin V. V., Shillington A., Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002;106:1477-1482.
24. Sitbon O., Humbert M., Nunes H. et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. JACC 2002;40:780-788.
25. McLaughlin V. V. Oral and subcutaneous prostacyclin analogs. In: Pulmonary circulation. Diseases and their treatment. Peacock A. J., Rubin L. J. (eds). Second edition. London: Arnold 2004:278-282.
26. Simonneau G., Barst R. J., Gate N. et al. Continuous subcutaneous infusion of trepostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. - Am J Respir Crit Care Med 2002;165:00-804.
27. Leuchte H. H., Behr J. Iloprostforidiopathicpulmonaryarterialhypertension. Expert Rev Cardiovasc Ther 2005;3:215-223.
28. Hsu H. H., Rubin Z. L. J. Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther 2006;6:1921-1930.
29. Olschewski H., Seeger W. Inhaled iloprost. In: Pulmonary circulation. Diseases and their treatment. Peacock A. J., Rubin L. J. (eds). Second edition. London: Arnold 2004:268-277.
30. Olschewski H., Simonneau G., Gate N. et al. for the Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. New Engl J Med 2002;347:322-329.
31. Hoeper M. M., Schwarze M., Ehlerding S. et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. New Engl J Med 2000;342:1866-1870.
32. Ono F., Nagaya N., Kyotani S. et al. Hemodynamic and hormonal effect of beraprost sodium, an oral active prostacyclin analogue, in patients with secondary precapillary pulmonary hypertension. Circulat J 2003;67:375-378.
33. Nagaya N., Uematsu M., Okano Y. et al. Effect of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial. JACC 1999;34:1188-1192.
34. Galii N., Humbert M., Vachiiry J.-L. et al., for the Arterial Pulmonary Hypertension And Beraprost European Trial (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebocontrolled trial. JACC 2002;39:1496-1502.
35. Barst R. J., McGoon M. D., McLaughlin V. et al., for the Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. JACC 2003;41:2119-2125.
36. Channick R. N., Sitbon O., Barst R. J. et al. Endothelin receptor antagonists in pulmonary artery hypertension. JACC 2004;43(suppl. S):62S-67S.
37. Helmersen D., Channick R. N., Rubin L. Endothelin receptor antagonists. - In: Pulmonary circulation. Diseases and their treatment. Peacock A. J., Rubin L. J. (eds). Second edition. London: Arnold 2004:294-301.
38. Channick R. N., Simonneau G., Sitbon O. et al. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary artery hypertension: A randomized placebo-controlled study. Lancet 2001;358:1119-1123.
39. Badesch D. B., Bodin F., Channick R. N. et al. Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in patients with pulmonary artery hypertension. Current Ther Res 2002;63:227-246.
40. Rubin L. J., Badesch D. B., Barst R. J. et al. Bosentan therapy for pulmonary artery hypertension. New Engl J Med 2002;346:896-903.
41. McLaughlin V. V., Sitbon O., Badesch D. B. et al. Survival with first-line bosentan in patients with pulmonary artery hypertension. Eur Respir J 2005;25:244-249.
42. Sitbon O., McLaughlin V. V., Badesch D. B. et al. Survival in patients with class III idiopathic pulmonary artery hypertension treated with first-line oral bosentan compared with historic cohort of patients started on intravenous epoprostenol. Thorax 2005;60:1025-1030.
43. Barst R. J., Langleben D., Frost A. et al. Sitaxsentan therapy for pulmonary artery hypertension. Am J Respir Crit Care Med 2004;169:441-447.
44. Barst R. J., Langleben D., Langleben D. et al. Treatment of pulmonary artery hypertension with the selective endothelin-A receptor antagonist sitaxsentan. JACC 2006;47:2049-2056.
45. Galii N., Badesch D. B., Oudiz R. et al. Ambrisentan therapy for pulmonary artery hypertension. JACC 2005;46:529-535.
46. Oudiz R., Galii N., Olschewski H. et al. Long-term ambrisentan therapy for the treatment of pulmonary artery hypertension. JACC 2009;54:1971-1981.
47. McGoon M. D., Frost A., Oudiz. R. et al. Ambrisentan therapy in patients with pulmonary artery hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009;135:122-129.
48. Sastry B. K. S., Narasimhan C., Reddy S. K., Raju B. S. Clinical efficacy of sildenafil in primary pulmonary hypertension. JACC 2004;43:1149-1153.
49. Galii N., Ghofrani H. A., Torbicki A. Sildenafil citrate therapy for pulmonary arterial hypertension. New Engl J Med 2005;353:2148-2157.
50. Wilkins M. R., Paul GA., Strange J. W. et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 2005;171:1292-1297.
51. Galii N., Brundage D. H., Ghofrani H. A. et al. Pulmonary arterial Hypertension and response to tadalafil (PHIRST). Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-2903.
52. Jing Z. D., Jiang X., Wu B. X. et al. Vardenafil therapy for patients with pulmonary arterial hypertension. A one-year, multicentre, open-label study. Heart 2009;95:1531-1536.
53. Chester M., Toumeux P., Seedorf F. et al. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2009;297:18-25.
54. Kim N. H. Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Eur Respir Rev 2010;19:68-71.
55. Anderson J. R., Nawarskas J. J. Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiol Rev 2010;18:148-162.
56. Beghett M., Galii N. Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. JACC 2009;53:733-740.